Michel Goedert is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Michel Goedert is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Cambridge and MRC Laboratory of Molecular Biology. Their research focuses on [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--, Alpha-synuclein, Protein aggregation, with particular emphasis on Alzheimer's Disease and Parkinson's Disease and FTD. With an h-index of 250, Goedert is among the most cited researchers in the neuroscience field.
Goedert's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Parkinson's Disease and FTD. Their research group has made significant contributions to the fields of Tau, Alpha-synuclein, Protein aggregation, publishing in high-impact journals including Brain, Nat Neurosci.
Based at University of Cambridge and MRC Laboratory of Molecular Biology, Goedert collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
- [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--
- [Tau[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [Alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- [Protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX--
¶ Collaborators and Research Network
[John Hardy[/researchers/[john-hardy[/researchers/[john-hardy[/researchers/[john-hardy--TEMP--/researchers)--FIX--, [Virginia M.-Y. Lee[/researchers/[virginia-lee[/researchers/[virginia-lee[/researchers/[virginia-lee--TEMP--/researchers)--FIX--, [John Q. Trojanowski[/researchers/[john-trojanowski[/researchers/[john-trojanowski[/researchers/[john-trojanowski--TEMP--/researchers)--FIX--
- [Researchers and Institutions Index[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Michel Goedert has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tau pathology in Alzheimer's disease. Nat Neurosci, 2015. DOI
- Alpha-synuclein in Lewy body disease. Brain, 2001. DOI
- ORCID profile: 0000-0002-5857-7687
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-02-26.
Michel Goedert is a Professor of Neurobiology at the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK, and the University of Cambridge. He is a world-renowned researcher whose work has fundamentally shaped our understanding of neurodegenerative diseases, particularly the role of protein aggregation.
- Alpha-Synuclein and Parkinson's Disease: Discovered that alpha-synuclein is the major protein in Lewy bodies, the characteristic inclusions found in Parkinson's disease brains.
- Tau and Alzheimer's Disease: Investigated tau protein aggregation and its role in Alzheimer's disease and other tauopathies.
- Prion-like Propagation: Demonstrated that misfolded proteins can propagate between cells and seed further aggregation, a concept with major implications for disease progression.
- Multiple System Atrophy: Identified alpha-synuclein as the disease protein in multiple system atrophy (MSA).
Dr. Goedert's discovery that alpha-synuclein is the main component of Lewy bodies was a landmark in Parkinson's disease research. This finding established that protein aggregation is a central mechanism in neurodegenerative diseases and opened new avenues for diagnostic and therapeutic development.
His research has also demonstrated that tau, alpha-synuclein, and other disease proteins can spread between brain regions in a prion-like manner, explaining the progressive nature of these disorders.
¶ Awards and Recognition
- The Brain Prize (2018) for discoveries of the role of alpha-synuclein and tau in neurodegenerative diseases
- The Gairdner Foundation International Award (2016)
- The Ernst Jung Prize for Science and Medicine (2016)
- Royal Society Fellow
- Commander of the Order of the British Empire (CBE)
- Over 400 publications with more than 60,000 citations
- [Parkinson's Disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease--TEMP--/diseases)--FIX--
- [Alpha-Synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Tau Protein[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX--
- [Lewy Body Dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--
- [MRC Laboratory of Molecular Biology[/institutions/[mrc-lmb[/institutions/[mrc-lmb[/institutions/[mrc-lmb--TEMP--/institutions)--FIX--
Michel Goedert is a Professor of Neurobiology at the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK, and the University of Cambridge. He is a world-renowned researcher whose work has fundamentally shaped our understanding of neurodegenerative diseases, particularly the role of protein aggregation.
- Alpha-Synuclein and Parkinson's Disease: Discovered that alpha-synuclein is the major protein in Lewy bodies, the characteristic inclusions found in Parkinson's disease brains.
- Tau and Alzheimer's Disease: Investigated tau protein aggregation and its role in Alzheimer's disease and other tauopathies.
- Prion-like Propagation: Demonstrated that misfolded proteins can propagate between cells and seed further aggregation, a concept with major implications for disease progression.
- Multiple System Atrophy: Identified alpha-synuclein as the disease protein in multiple system atrophy (MSA).
Dr. Goedert's discovery that alpha-synuclein is the main component of Lewy bodies was a landmark in Parkinson's disease research. This finding established that protein aggregation is a central mechanism in neurodegenerative diseases and opened new avenues for diagnostic and therapeutic development.
His research has also demonstrated that tau, alpha-synuclein, and other disease proteins can spread between brain regions in a prion-like manner, explaining the progressive nature of these disorders.
¶ Awards and Recognition
- The Brain Prize (2018) for discoveries of the role of alpha-synuclein and tau in neurodegenerative diseases
- The Gairdner Foundation International Award (2016)
- The Ernst Jung Prize for Science and Medicine (2016)
- Royal Society Fellow
- Commander of the Order of the British Empire (CBE)
- Over 400 publications with more than 60,000 citations
- [Parkinson's Disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease--TEMP--/diseases)--FIX--
- [Alpha-Synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Tau Protein[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX--
- [Lewy Body Dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--
- [MRC Laboratory of Molecular Biology[/institutions/[mrc-lmb[/institutions/[mrc-lmb[/institutions/[mrc-lmb--TEMP--/institutions)--FIX--
Michel Goedert is a Professor of Neurobiology at the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK, and the University of Cambridge. He is a world-renowned researcher whose work has fundamentally shaped our understanding of neurodegenerative diseases, particularly the role of protein aggregation.
- Alpha-Synuclein and Parkinson's Disease: Discovered that alpha-synuclein is the major protein in Lewy bodies, the characteristic inclusions found in Parkinson's disease brains.
- Tau and Alzheimer's Disease: Investigated tau protein aggregation and its role in Alzheimer's disease and other tauopathies.
- Prion-like Propagation: Demonstrated that misfolded proteins can propagate between cells and seed further aggregation, a concept with major implications for disease progression.
- Multiple System Atrophy: Identified alpha-synuclein as the disease protein in multiple system atrophy (MSA).
Dr. Goedert's discovery that alpha-synuclein is the main component of Lewy bodies was a landmark in Parkinson's disease research. This finding established that protein aggregation is a central mechanism in neurodegenerative diseases and opened new avenues for diagnostic and therapeutic development.
His research has also demonstrated that tau, alpha-synuclein, and other disease proteins can spread between brain regions in a prion-like manner, explaining the progressive nature of these disorders.
¶ Awards and Recognition
- The Brain Prize (2018) for discoveries of the role of alpha-synuclein and tau in neurodegenerative diseases
- The Gairdner Foundation International Award (2016)
- The Ernst Jung Prize for Science and Medicine (2016)
- Royal Society Fellow
- Commander of the Order of the British Empire (CBE)
- Over 400 publications with more than 60,000 citations
- [Parkinson's Disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease[/diseases/parkinson'[s-disease--TEMP--/diseases)--FIX--
- [Alpha-Synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Tau Protein[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX--
- [Lewy Body Dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--
- [MRC Laboratory of Molecular Biology[/institutions/[mrc-lmb[/institutions/[mrc-lmb[/institutions/[mrc-lmb--TEMP--/institutions)--FIX--
Dr. Goedert has authored over 400 publications on protein aggregation, including:
- Discovery of tau filaments in Alzheimer's disease
- Alpha-synuclein in Parkinson's disease
- [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- in ALS and FTD
- Prion-like propagation of protein aggregates
- Structure of neurodegenerative disease proteins
His work established the role of protein aggregation in neurodegeneration.
Dr. Goedert's research has shaped neurodegenerative disease understanding by:
- Defining the pathological classification of tauopathies
- Establishing alpha-synuclein as a Parkinson's disease target
- Enabling development of aggregate-specific therapeutics
- Creating tools for studying protein propagation
¶ Awards and Recognition
Dr. Goedert is a member of the Royal Society and has received the Brain Prize and other major awards for his discoveries.
- [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [Tau Protein[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX--
- [Alpha-Synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- Goedert M, et al. "Tau and alpha-synuclein in neurodegenerative disease." Nature Reviews Neuroscience. 2024.
- Goedert M. "Protein aggregation and neurodegeneration." Brain. 2023.
- Spillantini MG, Goedert M. "Synucleinopathies." Lancet Neurology. 2022.
- Goedert M, et al. "Tau pathology in Alzheimer's disease." [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. 2021.